Please login to the form below

Not currently logged in
Email:
Password:

Antares CEO Wotton resigns

He will move to Advanced Cell Technology

antares paul wottonAntares Pharma CEO Paul Wotton is to resign his position to take over as CEO at development-stage biotech company Advanced Cell Technology.

Wotton spent nearly six years in charge of New Jersey-based Antares, having previously served as CEO of Topigen Pharmaceutical.

His replacement at Antares is Eamonn Hobbs, a current board member of the company.  He has over 30 years of experience in the pharma and medical device sectors.

Hobbs was most recently president and CEO of Delcath Systems, a pharma and medical device company specialising in cancer treatment.

“We have worked closely with Eamonn over the past five years as board members and share his vision for the future,” said Leonard Jacob, chairman of the board of directors.

2nd July 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics